key: cord-0829371-m0mjg7gb authors: Wu, Kai; Choi, Angela; Koch, Matthew; Elbashir, Sayda; Ma, LingZhi; Lee, Diana; Woods, Angela; Henry, Carole; Palandjian, Charis; Hill, Anna; Jani, Hardik; Quinones, Julian; Nunna, Naveen; O’Connell, Sarah; McDermott, Adrian B; Falcone, Samantha; Narayanan, Elisabeth; Colpitts, Tonya; Bennett, Hamilton; Corbett, Kizzmekia S; Seder, Robert; Graham, Barney S; Stewart-Jones, Guillaume BE; Carfi, Andrea; Edwards, Darin K title: Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice date: 2021-10-07 journal: bioRxiv DOI: 10.1101/2021.04.13.439482 sha: b04abd23e001a5365a9c11d580cafb02cd4e56a8 doc_id: 829371 cord_uid: m0mjg7gb Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of a global pandemic. Safe and effective COVID-19 vaccines are now available, including mRNA-1273, which has shown 94% efficacy in prevention of symptomatic COVID-19 disease. However, the emergence of SARS-CoV-2 variants has led to concerns of viral escape from vaccine-induced immunity. Several variants have shown decreased susceptibility to neutralization by vaccine-induced immunity, most notably B.1.351 (Beta), although the overall impact on vaccine efficacy remains to be determined. Here, we present the initial evaluation in mice of 2 updated mRNA vaccines designed to target SARS-CoV-2 variants: (1) monovalent mRNA-1273.351 encodes for the spike protein found in B.1.351 and (2) mRNA-1273.211 comprising a 1:1 mix of mRNA-1273 and mRNA-1273.351. Both vaccines were evaluated as a 2-dose primary series in mice; mRNA-1273.351 was also evaluated as a booster dose in animals previously vaccinated with mRNA-1273. The results demonstrated that a primary vaccination series of mRNA-1273.351 was effective at increasing neutralizing antibody titers against B.1.351, while mRNA-1273.211 was effective at providing broad cross-variant neutralization. A third (booster) dose of mRNA-1273.351 significantly increased both wild-type and B.1.351-specific neutralization titers. Both mRNA-1273.351 and mRNA-1273.211 are being evaluated in pre-clinical challenge and clinical studies. Since the declaration of a global pandemic by the World Health Organization on March 11, 45 2020, infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led 46 to approximately 4.7 million deaths worldwide [1, 2] . Shortly after the SARS-CoV-2 genetic K417N, E484K, N501Y, D614G, and A701V (Fig. 1) . To expand the breadth of coverage to 93 multiple circulating variants as well as the ancestral wild-type virus that is still circulating globally, The mRNA was encapsulated in an LNP through a modified ethanol-drop nanoprecipitation 117 process described previously [36] . Ionizable, structural, helper, and polyethylene glycol lipids 118 were briefly mixed with mRNA in an acetate buffer, pH 5.0, at a ratio of 2.5:1 (lipids:mRNA). The mixture was neutralized with Tris-HCl, pH 7.5, sucrose was added as a cryoprotectant, and 120 the final solution was sterile-filtered. Vials were filled with formulated LNP and stored frozen at 121 -70°C until further use. The drug product underwent analytical characterization-which included 122 the determination of particle size and polydispersity, encapsulation, mRNA purity, double-123 stranded RNA content, osmolality, pH, endotoxin, and bioburden-and the material was deemed 124 acceptable for in vivo study. 136 Microtiter plates (96-well; Thermo) were coated with 1 µg/mL S-2P protein (Genscript) 137 corresponding to the S protein of the Wuhan-Hu-1 virus. After overnight incubation at 4°C, plates 138 were washed four times with PBS/0.05% Tween-20 and blocked for 1.5 hours at 37°C 139 (SuperBlock-Thermo). After washing, five-fold serial dilutions of mouse serum were added (assay Table 1 , were cloned into a pCAGGS vector. (Table 1) . High levels of binding antibody were elicited by vaccination in all animals 2 weeks after the 180 first and second injection, with 4.5 to 9.4-fold increased S-2P binding titers measured after the 181 second dose (Fig. 2b) . Slightly lower antibody levels were observed for mRNA-1273.351 (Fig. 2c,d) , although the approximate 2-fold difference was Table 1 , some of the mutations in these variants were different from both the Wuhan- (Fig. 3a) . High levels of binding antibody were elicited by vaccination with mRNA-1273, with peak 214 titers measured 2 weeks after the second dose (Fig. 3b) . After an initial drop in antibody levels, 215 titers were stable over the 7-month monitoring period. Following the mRNA-1273.351 booster 216 injection, antibody levels dramatically rose, exceeding the previously measured peak for both the (Fig. 3c,d) . The difference between the 2 assays 227 narrowed to 2-fold following the booster dose (Fig. 3c,e) ; the GMT of 15,524 against B.1.351 was 228 ~1.5 fold higher than the peak titer against D614G 2 weeks after the second dose (Fig. 3c) . Animals 229 vaccinated at the 0.1 µg dose level had lower titers, but similar trends for binding antibody and 230 neutralization titers were observed (data not shown). In this study, mRNA-1273.351 and mRNA-1273.211 were evaluated in mice as both a primary The authors declare that the data supporting the findings of this study are available within this 319 article. Employees of the study sponsor, Moderna, Inc., contributed to the study design, data collection, 322 analysis and interpretation, and writing of the report. Table 1 . S-protein substitutions in SARS-CoV-2 variants evaluated in this study. A pneumonia outbreak 329 associated with a new coronavirus of probable bat origin The species Severe acute respiratory syndrome-related 331 coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 Cryo-EM 333 structure of the 2019-nCoV spike in the prefusion conformation An 335 mRNA Vaccine against SARS-CoV-2 -Preliminary Report Efficacy and Safety of 337 the mRNA-1273 SARS-CoV-2 Vaccine FDA (2021) COVID-19 Vaccines Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Spike mutation D614G 344 alters SARS-CoV-2 fitness Evaluating the Effects 346 of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant Structure, function, 352 and antigenicity of the SARS-CoV-2 spike glycoprotein Functional assessment of cell entry and receptor usage for 354 SARS-CoV-2 and other lineage B betacoronaviruses Structural and Functional Basis of 356 SARS-CoV-2 Entry by Using Human ACE2 Cell entry mechanisms of 358 SARS-CoV-2 CoV-2 Recombinant Spike Protein Nanoparticle Vaccine Safety and 362 Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates Safety 365 and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults N-terminal 368 domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 1.351 and P.1 escape from neutralizing antibodies Decreased neutralization 374 of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect 378 recognition by polyclonal human plasma antibodies CoV-2 variants B.1.351 and B.1.1.7. Nature CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and 383 Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global 386 SARS-CoV-2 Variant Spikes Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant Serum 391 Neutralizing Activity Elicited by mRNA-1273 Vaccine Safety and 393 efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim 394 analysis of four randomised controlled trials in Brazil, South Africa, and the UK ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 7): an exploratory analysis of a randomised controlled trial Safety and 400 Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 CoV2373 Covid-19 Vaccine against the B.1.351 Variant Evidence for increased 405 breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated 406 individuals Safety and 408 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months Serum Neutralizing 410 Activity of mRNA-1273 Against SARS-CoV-2 Variants mRNA-1273 412 protects against SARS-CoV-2 beta infection in nonhuman primates Impact of mRNA 414 chemistry and manufacturing process on innate immune activation Optimization 416 of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 420 Influenza Viruses Multi-antigenic 422 human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much 426 Lower Doses Generation of VSV pseudotypes using recombinant DeltaG-VSV for studies on 428 virus entry, identification of entry inhibitors, and immune responses to vaccines SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness Safety and immunogenicity of SARS-434 CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis Innate transcriptional 436 effects by adjuvants on the magnitude, quality, and durability of HIV envelope Structure of the SARS-CoV-2 spike 439 receptor-binding domain bound to the ACE2 receptor is listed as text above each plot. The horizontal dotted line indicates the lower limit of quantitation 469 for NAb titer at 40 ID50.